Yukimoto Ishii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yukimoto Ishii has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Satoshi Asai
Nihon University School of Medicine
8 shared publicationsShigeru Suzuki
Nihon University School of Medicine
8 shared publicationsTadatoshi Takayama
Nihon University School of Medicine
7 shared publicationsTadashi Kohno
6 shared publicationsTomohisa Kohno
5 shared publicationsAsuka Ito
4 shared publications
Latest Publications
- 18 November 2009
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 66 (2) , 333-343
Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?
S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0.4:1. CYP2A6 genetic polymorphism and dihydropyrimidine dehydrogenase (DPD) inhibition are important for the antitumor effect of S-1. Exploiting the usefulness of the 2-13C-uracil breath test (UrBT) as an indicator of DPD activity, we examined whether the results of CYP2A6 genetic polymorphism analysis and UrBT could be used to predict the antitumor effect of S-1.
- 18 November 2009
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 66 (2) , 333-343
Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?
S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0.4:1. CYP2A6 genetic polymorphism and dihydropyrimidine dehydrogenase (DPD) inhibition are important for the antitumor effect of S-1. Exploiting the usefulness of the 2-13C-uracil breath test (UrBT) as an indicator of DPD activity, we examined whether the results of CYP2A6 genetic polymorphism analysis and UrBT could be used to predict the antitumor effect of S-1.
- 1 September 2008
- Vol. 35 (9) , 1583-6
[Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].
We report three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 with CPT-11. Case 1: A total gastrectomy was performed for a gastric cancer located in the lower to upper body of the stomach (T3 (SE), N2, H0, P0, por 2, stage III B). Abdominal computed-tomography (CT) revealed a solitary liver metastasis in the S8 subsegment of the liver. We treated the patient with S-1 combined with CPT-11. Abdominal CT revealed a complete response (CR) after 5 courses. Case 2: Sigmoidectomy and partial resection of small intestine and abdominal wall were performed for sigmoid colon cancer. The intraoperative findings revealed liver metastases in left lobe of the liver (Si, N1, H1, P0, M0, tub 1, stage IV). After surgery, the patient was treated with S-1 combined with CPT-11. Abdominal CT demonstrated CR after 5 courses. Case 3: Laparoscopic right hemicolectomy was performed for ascending colon cancer (SE, N1, H0, P0, M0, tub 1, stage III a). Abdominal CT showed a solitary liver metastasis in the S6 subsegment of the liver 3 months after surgery. We treated the patient with S-1 combined with CPT-11. Abdominal CT revealed CR after 3 courses. The three cases are alive without any signs of recurrence.
- 1 September 2008
- Vol. 35 (9) , 1583-6
[Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].
We report three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 with CPT-11. Case 1: A total gastrectomy was performed for a gastric cancer located in the lower to upper body of the stomach (T3 (SE), N2, H0, P0, por 2, stage III B). Abdominal computed-tomography (CT) revealed a solitary liver metastasis in the S8 subsegment of the liver. We treated the patient with S-1 combined with CPT-11. Abdominal CT revealed a complete response (CR) after 5 courses. Case 2: Sigmoidectomy and partial resection of small intestine and abdominal wall were performed for sigmoid colon cancer. The intraoperative findings revealed liver metastases in left lobe of the liver (Si, N1, H1, P0, M0, tub 1, stage IV). After surgery, the patient was treated with S-1 combined with CPT-11. Abdominal CT demonstrated CR after 5 courses. Case 3: Laparoscopic right hemicolectomy was performed for ascending colon cancer (SE, N1, H0, P0, M0, tub 1, stage III a). Abdominal CT showed a solitary liver metastasis in the S6 subsegment of the liver 3 months after surgery. We treated the patient with S-1 combined with CPT-11. Abdominal CT revealed CR after 3 courses. The three cases are alive without any signs of recurrence.
- 1 November 2007
- Published by Wolters Kluwer Health in Pancreas
- Vol. 35 (4) , 313-319
Evaluation of Pancreatic Exocrine Secretion Using 13C-Dipeptide (Benzoyl-L-Tyrosyl-[1-13C]Alanine) Breath Test
We investigated whether a breath test using benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala) allows assessment of pancreatic exocrine function. Benzoyl-L-tyrosyl-[1-13C]alanine was orally administered, and changes in 13CO2 were expressed as Δ‰. The breath test was performed in chronic pancreatitis patients and healthy subjects in a preliminary study and, subsequently, in 17 pancreatoduodenectomy patients, to examine the difference between the results obtained at the times of pancreatic tube insertion and removal, the relationship between breath test results after tube removal and the volume of pancreatic juice drained, and the difference in results between the presence versus the absence of histological changes of chronic pancreatitis. The Δ‰ was lower in the chronic pancreatitis patients than in healthy subjects. In the postoperative patients, the Δ‰ was higher at tube insertion than at tube removal. The correlations of the Δ‰ with the maximum volume of pancreatic juice, its mean volume, and pancreatic juice amylase levels were 0.865, 0.757, and 0.853, respectively. The Δ‰ was lower in 11 patients with that in 6 patients without histological changes of chronic pancreatitis. These results suggest that the Bz-Tyr-Ala breath test can measure pancreatic exocrine function.
- 1 November 2007
- Published by Wolters Kluwer Health in Pancreas
- Vol. 35 (4) , 313-319
Evaluation of Pancreatic Exocrine Secretion Using 13C-Dipeptide (Benzoyl-L-Tyrosyl-[1-13C]Alanine) Breath Test
We investigated whether a breath test using benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala) allows assessment of pancreatic exocrine function. Benzoyl-L-tyrosyl-[1-13C]alanine was orally administered, and changes in 13CO2 were expressed as Δ‰. The breath test was performed in chronic pancreatitis patients and healthy subjects in a preliminary study and, subsequently, in 17 pancreatoduodenectomy patients, to examine the difference between the results obtained at the times of pancreatic tube insertion and removal, the relationship between breath test results after tube removal and the volume of pancreatic juice drained, and the difference in results between the presence versus the absence of histological changes of chronic pancreatitis. The Δ‰ was lower in the chronic pancreatitis patients than in healthy subjects. In the postoperative patients, the Δ‰ was higher at tube insertion than at tube removal. The correlations of the Δ‰ with the maximum volume of pancreatic juice, its mean volume, and pancreatic juice amylase levels were 0.865, 0.757, and 0.853, respectively. The Δ‰ was lower in 11 patients with that in 6 patients without histological changes of chronic pancreatitis. These results suggest that the Bz-Tyr-Ala breath test can measure pancreatic exocrine function.
- 1 June 2007
- Published by Elsevier in Translational Research
- Vol. 149 (6) , 298-303
Measurement of extra-pancreatic secretory function by 13C-dipeptide breath test
- 1 June 2007
- Published by Elsevier in Translational Research
- Vol. 149 (6) , 298-303
Measurement of extra-pancreatic secretory function by 13C-dipeptide breath test
- 1 January 2007
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 42 (2) , 207-214
Usefulness of rectally administering [1-13C]-butyrate for breath test in patients with active and quiescent ulcerative colitis
Objective. Impaired butyrate metabolism plays a part in ulcerative colitis (UC). To assess the usefulness of measuring butyrate metabolism as an indication of inflammatory activity, we investigated the rate of butyrate metabolism by breath test after administering [1-13C]-butyrate rectally to patients with UC. Material and methods. Thirty-eight UC patients (22 active, 16 quiescent) and 15 healthy controls were given [1-13C]-butyrate enemas. The 13CO2 production rate was measured by breath test using an infrared spectrometric analyzer. Results. The quantity of expired 13CO2 was significantly lower in the active than in the quiescent UC and control groups. Cumulative 13CO2 production at 240 min showed significant negative correlations with the clinical activity index (r= −0.65, pr= −0.63, p=0.0001) and histology (r= −0.71, p13CO2 production rate was significantly increased in the quiescent stage as compared with the active stage in six UC patients, in whom clinical remission was achieved, in accordance with improvements in the clinical activity index, the endoscopic activity index, histology and fecal butyrate concentrations. Significant inverse correlations between the cumulative 13CO2 production rate and these three parameters were seen in these six UC patients assessed in both the active and quiescent stages. Conclusions. Measurement of expired 13CO2 after rectally administering [1-13C]-butyrate in active and quiescent UC appears to be a promising and reliable method for evaluating disease activity and metabolic changes associated with amelioration of inflammation.
- 1 January 2007
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 42 (2) , 207-214
Usefulness of rectally administering [1-13C]-butyrate for breath test in patients with active and quiescent ulcerative colitis
Objective. Impaired butyrate metabolism plays a part in ulcerative colitis (UC). To assess the usefulness of measuring butyrate metabolism as an indication of inflammatory activity, we investigated the rate of butyrate metabolism by breath test after administering [1-13C]-butyrate rectally to patients with UC. Material and methods. Thirty-eight UC patients (22 active, 16 quiescent) and 15 healthy controls were given [1-13C]-butyrate enemas. The 13CO2 production rate was measured by breath test using an infrared spectrometric analyzer. Results. The quantity of expired 13CO2 was significantly lower in the active than in the quiescent UC and control groups. Cumulative 13CO2 production at 240 min showed significant negative correlations with the clinical activity index (r= −0.65, pr= −0.63, p=0.0001) and histology (r= −0.71, p13CO2 production rate was significantly increased in the quiescent stage as compared with the active stage in six UC patients, in whom clinical remission was achieved, in accordance with improvements in the clinical activity index, the endoscopic activity index, histology and fecal butyrate concentrations. Significant inverse correlations between the cumulative 13CO2 production rate and these three parameters were seen in these six UC patients assessed in both the active and quiescent stages. Conclusions. Measurement of expired 13CO2 after rectally administering [1-13C]-butyrate in active and quiescent UC appears to be a promising and reliable method for evaluating disease activity and metabolic changes associated with amelioration of inflammation.
- Open Access
- 18 January 2006
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 4 (1) , 3
A case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resection
Background: An oral combined fluoropyrimidine anticancer drug, tegafur/gimeracil/oteracil potassium (S-1), has recently been used alone or in combination for colon cancer. Case presentation: The patient was a 42-year-old man with sigmoid colon cancer with direct invasion of the urinary bladder and multiple costal metastases. A diagnosis of T4, M1, stage IV sigmoid colon cancer was made, and curative resection was considered impossible. S-1 at 50 mg/m2 was administered by oral route from day 1 to day 14. Irinotecan (CPT-11) at 40 mg/m2 was administered by intravenous day 1 and 15. This treatment was followed by 2 weeks absent period, and repeated every 4 weeks. Six cycles of administration were performed in total. Following this treatment, the multiple costal metastases resolved. Down-staging to T3, M0, stage IIA was achieved, and curative resection was judged to be possible. Conclusion: Occasional cases in which S-1/CPT-11 therapy was effective have been recently reported. The patient's tumor became resectable despite the discovery of colon cancer associated with bone metastasis at the initial examination, offering hope for cancer patients.
- 18 January 2006
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 4 (1) , 3
Open AccessA case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resection
Background: An oral combined fluoropyrimidine anticancer drug, tegafur/gimeracil/oteracil potassium (S-1), has recently been used alone or in combination for colon cancer. Case presentation: The patient was a 42-year-old man with sigmoid colon cancer with direct invasion of the urinary bladder and multiple costal metastases. A diagnosis of T4, M1, stage IV sigmoid colon cancer was made, and curative resection was considered impossible. S-1 at 50 mg/m2 was administered by oral route from day 1 to day 14. Irinotecan (CPT-11) at 40 mg/m2 was administered by intravenous day 1 and 15. This treatment was followed by 2 weeks absent period, and repeated every 4 weeks. Six cycles of administration were performed in total. Following this treatment, the multiple costal metastases resolved. Down-staging to T3, M0, stage IIA was achieved, and curative resection was judged to be possible. Conclusion: Occasional cases in which S-1/CPT-11 therapy was effective have been recently reported. The patient's tumor became resectable despite the discovery of colon cancer associated with bone metastasis at the initial examination, offering hope for cancer patients.
- 1 March 2005
- Published by Elsevier in Journal of Surgical Research
- Vol. 124 (1) , 9-13
Ornithine breath test as a method to evaluate functional liver volume1
- 1 March 2005
- Published by Elsevier in Journal of Surgical Research
- Vol. 124 (1) , 9-13
Ornithine breath test as a method to evaluate functional liver volume1
- 1 October 2003
- Published by Elsevier in Journal of Surgical Research
- Vol. 114 (2) , 120-125
L-[1- 13 C] phenylalanine breath test reflects histological changes in the liver
- 1 October 2003
- Published by Elsevier in Journal of Surgical Research
- Vol. 114 (2) , 120-125
L-[1- 13 C] phenylalanine breath test reflects histological changes in the liver
- 1 June 2003
- Published by Elsevier in Journal of Surgical Research
- Vol. 112 (1) , 38-42
l-[1-13C] phenylalanine breath test reflects phenylalanine hydroxylase activity of the whole liver
- 1 June 2003
- Published by Elsevier in Journal of Surgical Research
- Vol. 112 (1) , 38-42
l-[1-13C] phenylalanine breath test reflects phenylalanine hydroxylase activity of the whole liver
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A606-606
Cyclooxygenase-2 (COX-2) is highly expressed in human rectal carcinoids
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A606-606
Cyclooxygenase-2 (COX-2) is highly expressed in human rectal carcinoids